Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Todd Lehman Joins LumaBridge as Vice President and Head of Business Development

LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.

Todd brings nearly 20 years of client services, commercial and clinical operations experience to LumaBridge. His expertise spans multiple therapeutic areas, with a particular emphasis on oncology and ophthalmology. Prior to joining LumaBridge, Todd held various leadership roles in operations and portfolio management with a focus on the biotech customer at PPD, a Thermo Fisher Scientific company. Prior to PPD, he led the Medical Affairs, Global Clinical & Regulatory Operations at Alcon Laboratories. Todd began his career in the clinical research industry in 2004 at Rx Development Resources, the CRO division of Sirion Therapeutics. Todd holds an M.S. in biomedical engineering and a B.S. in chemical engineering, from the University of South Florida.

"We are thrilled to welcome Todd to the LumaBridge team," said David Boyle, Chief Executive Officer of LumaBridge. "Todd's extensive experience in the industry will play a pivotal role in driving our next phase of growth as we continue to scale our clinical trial capabilities."

"I'm honored to be joining LumaBridge at this exciting stage of growth in the company's evolution," said Todd Lehman. "I look forward to supporting the continued efforts of our customers in bringing innovative solutions to oncology patients."

About LumaBridge

LumaBridge is a specialty clinical research organization (CRO) focused on creating innovative clinical trial solutions for biopharma companies. Founded in 2014 as Cancer Insight, the company offers customized clinical trial guidance, strategic partnership, and personalized attention to each sponsor, accelerating the development of potential therapies.

LumaBridge builds on the success and experience of a seasoned team, led by Dr. George Peoples, to support drug development, accelerating therapies to patients and guiding biopharma companies through clinical and regulatory pathways. As part of their comprehensive CRO services, LumaBridge offers consultation on trial design and clinical development strategy.

For more information, visit lumabridge.com.

These press releases may also interest you

at 04:50
Mibro, the renowned smartwatch brand from Zhenshi Technology, a member of the Xiaomi ecological chain, has launched two new upgraded smartwatches -- Mibro T2, a lifestyle smartwatch to help people achieve the balance of life, work, and wellness;...

at 04:17
TECNO's premium sub-brand, PHANTOM, today launched the groundbreaking PHANTOM V Flip 5G ? its first-ever flip phone and latest flagship foldable device. The breakthrough smartphone sets a new standard for the integration of advanced technologies and...

22 sep 2023
Innovative technology brand, TECNO, today launched two new products ? its flagship debut flip smartphone PHANTOM V Flip 5G and the outstanding MEGABOOK T1 2023 14inch laptop ? at the Flip In Style TECNO Flagship Product Launch 2023 in Singapore. The...

22 sep 2023
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with...

22 sep 2023
Today marked the culmination of Think Together's month-long work with the Los Angeles Dodgers Foundation to support LA Reads, their literacy program with engaging and educational resources that make reading fun for everyone. In...

22 sep 2023
The "Silicon Photonics Market by application (Communications, Consumer electronics, and Others), component (Lasers, Modulators, and Photodetectors), component (lasers, modulators, and photo detectors) and geography (North America, APAC, Europe, South...

News published on and distributed by: